title: Targeting Akt in cell transfer immunotherapy for cancer.
abstract: Pharmacologic inhibitors of the serine/threonine kinase Akt, initially aimed at deranged oncogenic pathways in tumors, have recently been shown to act as immunomodulators that markedly enhance the antitumor properties of T cells. Repurposing Akt inhibitors to improve antitumor immunity may be viewed as a manifestation of a larger paradigmatic shift in which hallmark characteristics of cancer (e.g., immune evasion), rather than merely causal features (e.g., somatic mutations) can be exploited for therapeutic benefit.
authors.affiliation: Surgery Branch of National Cancer Institute; National Institutes of Health; Bethesda, MD USA; Department of Surgery; University of California Los Angeles; Los Angeles, CA USA.
authors.forename: Joseph G
authors.initials: JG
authors.lastname: Crompton
authors.affiliation: Surgery Branch of National Cancer Institute; National Institutes of Health ; Bethesda, MD USA.
authors.forename: Madhusudhanan
authors.initials: M
authors.lastname: Sukumar
authors.affiliation: Surgery Branch of National Cancer Institute; National Institutes of Health ; Bethesda, MD USA.
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Restifo
keywords: Akt inhibition; cell-based immunotherapy; immunometabolism